Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
Graeme Bell and others went on to clone mammalian versions of preproglucagon: a gene that encodes a large protein precursor, which is cleaved to produce glucagon and two glucagon-like peptides (GLP-1 and -2)
Some websites may estimate that retatrutide could become available in 2027 or 2028, but this has not been confirmed
This is standard advice for GLP-1 therapy, but it becomes even more critical during the transition
US$ 29.90
US$ 25.57
US$ 28.05
US$ 20.90
US$ 25.55
US$ 27.49
